logo
  

Gamma Communications Sees FY Results Slightly Above View; Stock Up

Shares of Gamma Communications Plc (GAMA.L) gained around 5 percent in the morning trading in London after the UK- based provider of communications services said its revenue and adjusted EBITDA, a key earnings metric, for the year 2014 is slightly ahead of the Board's original expectations.

The improvement reflects a strong demand in the business market for Gamma's portfolio of products. This positive performance was principally driven by growth in the number of channel partners in indirect business, significant contract wins in direct sales business, as well as continued strong growth in both Gamma SIP Trunks and active seats on Gamma's Cloud PBX services.

In its trading update, the company said its results will include exceptional items of 2.1 million pounds, including 1.3 million pounds of IPO costs and 0.6 million pounds due to the change in the fair value of contingent consideration relating to the Varidion acquisition. Share Based Payment charges will be 3.4 million pounds.

The Directors expect to propose a dividend in line with the policy that was stated in the Admission document.

The results for the full year are expected to be released in late March 2015.

In London, Gamma shares are currently trading at 266.66 pence, up 5.19 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
RELATED NEWS
Follow RTT